Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | INSR | P06213 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400196 | 0.93 | IGF1R (0.40) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL399411 | 0.87 | IGF1R (0.36) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL400731 | 0.86 | EGFR (0.33) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL400401 | 0.83 | TNK2 (0.36) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL399525 | 0.83 | F2 (0.34) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL397604 | 0.81 | IGF1R (0.49) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL399956 | 0.81 | AHR (0.32) | — | |
| SCHEMBL401747 | 0.80 | IGF1R (0.38) | IGF1RCYP3A4 | |
| SCHEMBL402211 | 0.80 | IGF1R (0.47) | EGFRINSRIGF1RCYP3A4KDR | |
| SCHEMBL402177 | 0.79 | IGF1R (0.40) | EGFRINSRIGF1RCYP3A4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | EGFR 155/4885INSR 27/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.